Format

Send to

Choose Destination
Oncoimmunology. 2014 Jun 25;3:e29311. eCollection 2014.

Personal neoantigen cancer vaccines: The momentum builds.

Author information

1
Broad Institute of Harvard and MIT; Cambridge, MA USA ; Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA.
2
Broad Institute of Harvard and MIT; Cambridge, MA USA ; The Division of Allergy, Immunology and Rheumatology; Department of Medicine; Massachusetts General Hospital; Boston, MA USA.
3
Broad Institute of Harvard and MIT; Cambridge, MA USA ; Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA.

Abstract

Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient's tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation.

KEYWORDS:

T cells; central tolerance; neoantigen; personalized; vaccine

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center